Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Prognostic Significance of ETP Phenotype and Minimal Residual Disease in T-ALL: A Children's Oncology Group Study

Brent Wood, Meenakshi Devidas, Ryan J Summers, Zhiguo Chen, Barbara L. Asselin, Karen R Rabin, Patrick A Zweidler-McKay, Naomi J Winick, Michael J. Borowitz, William L Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Kimberly P. Dunsmore, David Trent Teachey, Stuart S. Winter

Blood blood.2023020678.

https://doi.org/10.1182/blood.2023020678

Published: 2023

Includes: Supplemental data

Journal Articles

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Blood (2023) 142 (2): 172–184.

https://doi.org/10.1182/blood.2023019765

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis

Louise Guolla, Sara Breitbart, Farid Foroutan, Lehana Thabane, Mignon L. Loh, David T. Teachey, Elizabeth A. Raetz, Sumit Gupta

Blood (2023) 141 (24): 2944–2954.

https://doi.org/10.1182/blood.2022018899

Published: 2023

Includes: Supplemental data

Journal Articles

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey

Blood (2023) 141 (15): 1802–1811.

https://doi.org/10.1182/blood.2022018653

Published: 2023

Includes: Supplemental data

Journal Articles

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 141 (7): 704–712.

https://doi.org/10.1182/blood.2022016923

Published: 2023

Includes: Supplemental data

Journal Articles

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Blood (2022) 140 (Supplement 1): 7763–7765.

https://doi.org/10.1182/blood-2022-160272

Published: 2022

Journal Articles

The Role of Relapse Specific over-Expression of S100A8/A9 B Leukemic Cells in Promoting Chemoresistance

Clemence Aldebert, Emily Duan, Sylwia Jasinski, Talia H Ostrow, Isaiah Gonzalez, Aristotelis Tsirigos, Elizabeth A. Raetz, Nikki Ann Evensen, William L. Carroll

Blood (2022) 140 (Supplement 1): 6337–6338.

https://doi.org/10.1182/blood-2022-169273

Published: 2022

Journal Articles

Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia

Blood (2022) 140 (Supplement 1): 1273–1274.

https://doi.org/10.1182/blood-2022-167057

Published: 2022

Journal Articles

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 1722–1723.

https://doi.org/10.1182/blood-2022-165233

Published: 2022

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Xiaotian Wu, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2022) 140 (Supplement 1): 8969–8970.

https://doi.org/10.1182/blood-2022-160192

Published: 2022

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis

Blood (2022) 140 (Supplement 1): 1727–1729.

https://doi.org/10.1182/blood-2022-167157

Published: 2022

Journal Articles

Progenitor Sub-Populations in Treatment Resistant T-ALL

Blood (2022) 140 (Supplement 1): 1724–1726.

https://doi.org/10.1182/blood-2022-166521

Published: 2022

Journal Articles

Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children

Carolin Escherich, Wenan Chen, Satoshi Miyamoto, Yui Namikawa, Wenjian Yang, David T. Teachey, Zhenhua Li, Elizabeth A. Raetz, Eric C Larsen, Meenakshi Devidas, Paul L. Martin, W Paul Bowman, Gang Wu, Ching-Hon Pui, Stephen P. Hunger, Masatoshi Takagi, Jun J. Yang, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 990–991.

https://doi.org/10.1182/blood-2022-158556

Published: 2022

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

Sarah K Tasian, Deborah S Hunter, I-Ming L Chen, Richard C Harvey, Andrew J. Carroll, Elizabeth Wagner, Shalini C Reshmi, Michael J Borowitz, Brent L. Wood, Jeannie Daniel, Meenakshi Devidas, Elizabeth A. Raetz, Stephen P. Hunger, Albert Assad, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 6117–6118.

https://doi.org/10.1182/blood-2022-164699

Published: 2022

Journal Articles

The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 3458–3460.

https://doi.org/10.1182/blood-2022-159159

Published: 2022

Journal Articles

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732

Jennifer L. McNeer, Maureen M. O'Brien, Susan R. Rheingold, Meenakshi Devidas, Zhiguo Chen, Deepa Bhojwani, Anurag K. Agrawal, Brent Wood, Eugene Suh, Sarah Alexander, Tamara P. Miller, Olga Militano, Elizabeth A. Raetz, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2021-149478

Published: 2021

Journal Articles

Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3487.

https://doi.org/10.1182/blood-2021-151837

Published: 2021

Journal Articles

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Amanda M. Li, Karen R Rabin, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Maki Okada, Johann K Hitzler, Anne L Angiolillo, Elizabeth A. Raetz, Mignon L. Loh, Sumit Gupta, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2304.

https://doi.org/10.1182/blood-2021-148967

Published: 2021

NARROW

Prognostic Significance of ETP Phenotype and Minimal Residual Disease in T-ALL: A Children's Oncology Group Study

Genomic landscape of Down syndrome–associated acute lymphoblastic leukemia

Impact of vincristine-steroid pulses during maintenance for B-cell pediatric ALL: a systematic review and meta-analysis

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

The Role of Relapse Specific over-Expression of S100A8/A9 B Leukemic Cells in Promoting Chemoresistance

Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia

A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis

Progenitor Sub-Populations in Treatment Resistant T-ALL

Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non- CRLF2 -Rearranged JAK Pathway Alterations

The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732

Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only